Treace Medical Concepts

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Treace Medical Concepts (TMCI) reports stellar revenue growth and innovation plans

Treace Medical Concepts (TMCI) delivered exceptional revenue growth in 2022, exceeding expectations and showcasing strong market positioning. With a focus on innovation, specialized sales strategies, and complementary products, TMCI is poised for continued success. While challenges like sustaining growth exist, the company's strategic investments and upcoming product releases present promising opportunities for future expansion.

Treace Medical Concepts (TMCI) reports robust Q1 growth and raises full-year revenue guidance

Treace Medical Concepts (TMCI) delivered impressive Q1 2023 results, showcasing strong revenue growth and increased market penetration. With raised revenue guidance for the full year and a focus on strategic investments, TMCI is well-positioned for continued success and market expansion.

Treace Medical Concepts reports robust Q2 growth and strategic investments

Treace Medical Concepts (TMCI) delivered strong Q2 results with significant revenue growth, expanded market penetration, and strategic investments in growth initiatives.
While facing a net loss, the company improved adjusted EBITDA and raised full-year revenue guidance, supported by a robust financial position.
Challenges include managing expenses, pricing strategies, and surgeon satisfaction, but opportunities lie in upcoming product launches, reimbursement rates, and surgeon engagement.

Treace Medical Concepts reports strong Q3 revenue growth and outlines future growth strategies

Treace Medical Concepts delivered strong Q3 results with revenue up 23% YoY, despite challenges from soft surgery demand and delayed product launches.
The company's focus on innovation, market expansion, and operational efficiency positions it for future growth and improved financial performance.
While facing short-term challenges, Treace's strategic investments, strong cash position, and product pipeline offer opportunities for sustained growth and market leadership.
Overall, Treace's performance reflects resilience and adaptability in navigating market dynamics, with a clear focus on driving innovation and capturing market opportunities.

Treace Medical Concepts reports robust Q4 earnings and eyes market expansion

Treace Medical Concepts (TMCI) delivered strong financial results in Q4 2023, with revenue growth, positive adjusted EBITDA, and a positive outlook for 2024.
The company's focus on new technologies, market penetration, and efficient sales models positions it well for continued growth and market expansion.
While facing challenges in maintaining gross margins and optimizing sales team productivity, Treace remains optimistic about growth potential and strategic positioning.

Treace Medical Concepts reports robust Q1 growth amidst competitive challenges

Treace Medical Concepts demonstrates strong growth momentum and financial resilience in Q1 2024, driven by product innovation and strategic partnerships.
While facing challenges from increased competition and market pressures, the company remains agile with revised guidance and a focus on cost management.
Opportunities for expansion and differentiation through new product launches and market partnerships position Treace for continued success in the orthopedic medical device sector.

Treace Medical Concepts reports robust Q2 growth and eyes Medicare opportunities

Treace Medical Concepts (TMCI) delivered strong Q2 results and is poised for continued growth with a focus on innovation and market expansion.
While facing challenges in product launch and market competition, the company's commitment to R&D and leveraging regulatory changes provides a solid foundation for future success.
Opportunities in Medicare payment rate increases and new product introductions offer avenues for revenue growth and market leadership in the medical device industry.

Treace Medical Concepts reports Q3 growth, faces patent lawsuit

Treace Medical Concepts showed solid revenue growth in Q3 2024 despite facing a net loss. The company's Nanoplasty system and strategic focus on bunion cases present growth opportunities. Legal challenges and financial losses are key areas of concern.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PONTE VEDRA, Fla., July 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced it will host a Surgeon Advisor event at the Nasdaq MarketSite in New York City on Tuesday, September 20, 2022 at 9am ET. The event will include presentations from leading Lapiplasty® and Adductoplasty™ surgeons, as well as remarks from the Treace executive management team. The event will also feature new and recently launched product innovations.

Treace to Host Surgeon Advisor Event on September 20, 2022

PONTE VEDRA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 9, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Treace to Report Second Quarter 2022 Financial Results on August 9, 2022

Treace Medical Concepts (TMCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Treace Medical Concepts (TMCI) Moves 8.2% Higher: Will This Strength Last?

Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Danielle Antalffy - SVB Securities Operator Good day and thank you for standing by. Welcome to the Treace Medical Concepts' First Quarter 2022 Earnings Conference Call.

Treace Medical Concepts, Inc. (TMCI) CEO John Treace on Q1 2022 Results - Earnings Call Transcript

PONTE VEDRA, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2022.

Treace Medical Concepts Reports First Quarter 2022 Financial Results

PONTE VEDRA, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the publication of a peer-reviewed manuscript that details an interim dataset of its ALIGN3D™ multicenter, prospective clinical study in the Journal of Foot & Ankle Surgery.

Treace Announces Peer-Reviewed Publication of ALIGN3D™ Multicenter Prospective Clinical Data

PONTE VEDRA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has entered into a new five-year $150 million loan arrangement with MidCap Financial, comprising up to $120 million in term loans and a $30 million revolving credit facility. Proceeds from the new term loan refinanced the Company's existing $30 million term loan from CR Group LP. In addition, the new revolving credit facility will expand the Company's revolving credit capacity and replace the undrawn existing $10 million revolving credit facility from Silicon Valley Bank.

Treace Secures Up to $150 Million in Debt Financing

PONTE VEDRA, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Treace to Report First Quarter 2022 Financial Results on May 5, 2022

PONTE VEDRA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), announced today that it filed a lawsuit against Fusion Orthopedics, LLC, alleging infringement of multiple patents related to Treace's Lapiplasty® 3D Bunion Correction™ system. Treace's lawsuit also alleges copyright infringement, infringement of Treace's trademark rights and unfair competition. The suit was filed in the United States District Court for the District of Arizona, seeking injunctive relief and damages.

Treace Files Patent Infringement Suit To Protect Lapiplasty® Bunion Technology

Treace Medical Concepts, Inc. (TMCI) CEO John Treace on Q4 2021 Results - Earnings Call Transcript

PONTE VEDRA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2021.

Treace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results

PONTE VEDRA, Fla., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the podium presentation of the latest interim analysis from the ALIGN3D™ clinical study at the ongoing 2022 American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in Austin, Texas.

Treace Announces Updated ALIGN3D™ Data at the 2022 ACFAS Scientific Conference

PONTE VEDRA, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announces it will highlight new product innovations at the 2022 American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in Austin, Texas from February 24-27.

Treace Highlights New Product Innovations at the 2022 ACFAS Scientific Conference

PONTE VEDRA, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Thursday, March 3, 2022. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Treace to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

PONTE VEDRA, Fla., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the upcoming podium presentation of the latest interim analysis from the ALIGN3D™ clinical study at the 2022 American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference to be held in February 24-27 in Austin, Texas.

Treace to Announce Latest ALIGN3D™ Data at the 2022 ACFAS Scientific Conference

PONTE VEDRA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,213,333, titled “Bone Positioning and Preparing Guide Systems and Methods.”

Treace Announces Grant of U.S. Patent on Instrumented Bunion Correction

The stock price of Treace Medical Concepts, Inc. (NASDAQ: TMCI) increased by 14.86% in the most recent trading session. This is why it happened.

Treace Medical Concepts Stock (TMCI): Why The Price Jumped

PONTE VEDRA, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 4:30 p.m. Eastern Time.

Treace to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

PONTE VEDRA, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced today that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,185,359, titled “Bone Positioning Guide,” and also issued a Notice of Allowance for the Company's pending U.S. Patent Application No. 17/353,431, titled “Bone Positioning and Preparing Guide Systems and Methods.”

Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Bunion Correction

PONTE VEDRA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a virtual fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, beginning at approximately 9:20 am ET.

Treace Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Treace Medical Concepts' (TMCI) CEO John Treace on Q3 2021 Results - Earnings Call Transcript

PONTE VEDRA, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, announced that the United States Patent and Trademark Office granted to the Company U.S. Patent No. 11,147,590, titled “Bone Positioning and Cutting System and Method.” This patent is directed generally to methods of performing a bunion surgery to correct a first metatarsal alignment.

Treace Announces Grant of Additional U.S. Patent on Instrumented Bunion Correction

PONTE VEDRA, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021. Company management will host a conference call to discuss financial results beginning at 4:30 p.m. ET.

Treace to Report Third Quarter 2021 Financial Results on November 4, 2021

PONTE VEDRA, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the presentation of new data at the ongoing 2021 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Charlotte, North Carolina. Updated interim analysis from the ALIGN3D™ clinical study demonstrated positive radiographic and patient-reported outcomes starting at 6 weeks and maintained at 24 months following the Lapiplasty® procedure.

Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting

PONTE VEDRA, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the commercial launch of the Adductoplasty™ System. The Adductoplasty™ System brings together Treace's implants and precision instrumentation for the first comprehensive system designed for reproducible realignment, stabilization, and fusion of the midfoot. Midfoot deformities may occur in up to 30% of hallux valgus (bunion) patients.1 ,2

News for Treace Medical Concepts Stock (TMCI)